Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Wirden

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Jac-Antimicrobial Resistance|December 11, 2024
Clearance of archived integrase strand transfer inhibitors resistance mutations in people with virologically suppressed HIV infectionBasma Abdi, Romain Palich, Sophie Seang, et al.
Antiviral Therapy|July 21, 2004
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patientsBernard Masquelier, Catherine Tamalet, Brigitte Montès, et al.
The Journal of Antimicrobial Chemotherapy|January 9, 2025
Major role of dolutegravir in the emergence of the S147G integrase resistance mutationMarc Wirden, Basma Abdi, Sidonie Lambert-Niclot, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 10, 2020
Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2Marc Wirden, Linda Feghoul, Mélanie Bertine, et al.
The Journal of Antimicrobial Chemotherapy|June 22, 2026
Add-on efficacy of doravirine in PLWHIV with virological failure and low-level viremiaVincent Calvez, Charlotte Charpentier, Enagnon Kazali Alidjinou, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2021
Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoirBasma Abdi, Sidonie Lambert-Niclot, Marc Wirden, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2025
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stableCathia Soulie, Rachid Agher, Antoine Fauchois, et al.
The Journal of Antimicrobial Chemotherapy|June 11, 2013
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitorsSlim Fourati, Benoit Visseaux, Daniele Armenia, et al.
The Journal of Antimicrobial Chemotherapy|May 20, 2021
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patientsCharlotte Charpentier, Alexandre Storto, Cathia Soulié, et al.
AIDS (London, England)|July 23, 2020
No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infectionBasma Abdi, Thuy Nguyen, Sophie Brouillet, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Jac-Antimicrobial Resistance|December 11, 2024
Clearance of archived integrase strand transfer inhibitors resistance mutations in people with virologically suppressed HIV infectionBasma Abdi, Romain Palich, Sophie Seang, et al.
Antiviral Therapy|July 21, 2004
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patientsBernard Masquelier, Catherine Tamalet, Brigitte Montès, et al.
The Journal of Antimicrobial Chemotherapy|January 9, 2025
Major role of dolutegravir in the emergence of the S147G integrase resistance mutationMarc Wirden, Basma Abdi, Sidonie Lambert-Niclot, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|August 10, 2020
Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2Marc Wirden, Linda Feghoul, Mélanie Bertine, et al.
The Journal of Antimicrobial Chemotherapy|June 22, 2026
Add-on efficacy of doravirine in PLWHIV with virological failure and low-level viremiaVincent Calvez, Charlotte Charpentier, Enagnon Kazali Alidjinou, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2021
Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoirBasma Abdi, Sidonie Lambert-Niclot, Marc Wirden, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2025
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stableCathia Soulie, Rachid Agher, Antoine Fauchois, et al.
The Journal of Antimicrobial Chemotherapy|June 11, 2013
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitorsSlim Fourati, Benoit Visseaux, Daniele Armenia, et al.
The Journal of Antimicrobial Chemotherapy|May 20, 2021
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patientsCharlotte Charpentier, Alexandre Storto, Cathia Soulié, et al.
AIDS (London, England)|July 23, 2020
No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infectionBasma Abdi, Thuy Nguyen, Sophie Brouillet, et al.
Pageof 10